快速的iPSC包容性病变模型揭示了α-synuclein包容性的形成,后果和分子亚型
Isabel Lam1, Alain Ndayisaba2, Amanda J Lewis3
1Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA, USA; Division of Movement Disorders, American Parkinson Disease Association (APDA) Center for Advanced Research and MSA Center of Excellence, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
Neuron
|July 30, 2024
概括
新的诱导多能干细胞模型迅速产生与神经退行相关的蛋白质含有. 这些模型揭示了不同的包含类型,并确定了影响神经元存活的因素,有助于开发用于蛋白质病变的药物.
科学领域:
- 神经科学是一个神经科学.
- 细胞生物学 细胞生物学
- 遗传学 遗传学 是一个
背景情况:
- 包含中的蛋白质聚合是神经退行症的核心,但人们对其了解甚少.
- 现有的患者衍生诱导多能干细胞 (iPSC) 模型缺乏可复制性和研究包容性的速度.
研究的目的:
- 开发可选的iPSC模型,用于在中枢神经系统 (CNS) 细胞中快速,可重复生成的蛋白质内置.
- 调查包括的异质性及其对神经元存活的影响.
- 为了识别参与纳入毒性的分子参与者.
主要方法:
- 使用piggyBac或向转基因的工程iPSC模型,以在类似大脑的水平上表达容易聚合的蛋白质.
- 通过转基因表达或纤维细胞播种开发了α-synuclein包容症的皮层神经元模型.
- 进行了蛋白质基因和物理相互作用屏幕.
主要成果:
- 确定了不同的包容类别,包括神经保护性p62-阳性和神经毒性脂质丰富的包容,反映了患者大脑中的包容.
- 观察到,包含亚型之间的融合事件影响神经元的存活率.
- 精确的候选人RNA处理和actin-cytoskeleton蛋白质 (例如RhoA) 隔离在增加毒性的含有物中.
结论:
- 为研究神经退行性疾病开发了可处理的基于iPSC的"包容性病"模型.
- 这些模型有助于功能性基因组分析和蛋白质病变的药物发现.
- 这些发现突出了不同类型的包容性和它们在神经元死亡中的作用的复杂相互作用.
相关概念视频
01:21EPS and iPS Cells in Disease Research
2.8K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
2.8K
03:03Amyloid Fibrils
9.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.5K